Oral semaglutide in patients with type 2 diabetes and cardiovascular disease, renal impairment, or other comorbidities, and in older patients

References

• American Diabetes Association. Economic costs of diabetes in the U.S. in 2017. Diabetes Care. 2018;41:917–928.
   PubMed Web of Science ®Google Scholar
• Harding JL, Pavkov ME, Magliano DJ, et al. Global trends in diabetes complications: a review of current evidence. Diabetologia. 2019;62:3–16.
   PubMed Web of Science ®Google Scholar
• National Institute of Diabetes and Digestive and Kidney Diseases. Diabetes in America. 3rd ed. 2018 [cited 2020 May 25]. Available from: https://www.niddk.nih.gov/about-niddk/strategic-plans-reports/diabetes-in-america-3rd-edition#CandF
   Google Scholar
• International Diabetes Federation. IDF Atlas: 9th ed. 2019 [cited 2020 May 25]. Available from: http://www.diabetesatlas.org
   Google Scholar
• American Diabetes Association. 12. Older adults: Standards of Medical Care in Diabetes 2020. Diabetes Care. 2020;43(Suppl 1):S152–S162.
   PubMed Web of Science ®Google Scholar
• Gregg EW, Cheng YJ, Srinivasan M, et al. Trends in cause-specific mortality among adults with and without diagnosed diabetes in the USA: an epidemiological analysis of linked national survey and vital statistics data. Lancet. 2018;391(10138):2430–2440.
   PubMed Web of Science ®Google Scholar
• Taylor KS, Heneghan CJ, Farmer AJ, et al. All-cause and cardiovascular mortality in middle-aged people with type 2 diabetes compared with people without diabetes in a large U.K. primary care database. Diabetes Care. 2013;36(8):2366–2371.
   PubMed Web of Science ®Google Scholar
• Luyckx VA, Tonelli M, Stanifer JW. The global burden of kidney disease and the sustainable development goals. Bull World Health Organ. 2018;96(6):414–422D.
   PubMed Web of Science ®Google Scholar
• Bailey RA, Wang Y, Zhu V, et al. Chronic kidney disease in US adults with type 2 diabetes: an updated national estimate of prevalence based on Kidney Disease: Improving Global Outcomes (KDIGO) staging. BMC Res Notes. 2014;7:415.
   PubMedGoogle Scholar
• Wang Y, Katzmarzyk PT, Horswell R, et al. Kidney function and the risk of cardiovascular disease in patients with type 2 diabetes. Kidney Int. 2014;85(5):1192–1199.
   PubMed Web of Science ®Google Scholar
• De Cosmo S, Lamacchia O, Pacilli A, et al. Normoalbuminuric renal impairment and all-cause mortality in type 2 diabetes mellitus. Acta Diabetol. 2014;51(4):687–689.
   PubMed Web of Science ®Google Scholar
• Astor BC, Matsushita K, Gansevoort RT, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int. 2011;79(12):1331–1340.
   PubMed Web of Science ®Google Scholar
• Gansevoort RT, Matsushita K, van der Velde M, et al. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int. 2011;80(1):93–104.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 4. Comprehensive medical evaluation and assessment of comorbidities: Standards of Medical Care in Diabetes 2020. Diabetes Care. 2020;43(Suppl 1):S37–S47.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes 2020. Diabetes Care. 2020;43(Suppl 1):S98–S110.
   PubMed Web of Science ®Google Scholar
• Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary. Endocr Pract. 2020;26:107–139.
   PubMed Web of Science ®Google Scholar
• Buse JB, Wexler DJ, Tsapas A, et al. 2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and The European Association for the Study of Diabetes (EASD). Diabetes Care. 2020;43(2):487–493.
   PubMed Web of Science ®Google Scholar
• Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–1844.
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322.
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121–130.
   PubMed Web of Science ®Google Scholar
• Buckley ST, Bækdal TA, Vegge A, et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci Transl Med. 2018;10(467):eaar7047.
   Web of Science ®Google Scholar
• DiBonaventura MD, Wagner JS, Girman CJ, et al. Multinational internet-based survey of patient preference for newer oral or injectable type 2 diabetes medication. Patient Prefer Adherence. 2010;4:397–406.
   PubMed Web of Science ®Google Scholar
• Rybelsus® (semaglutide) prescribing information [updated Jan 2020; cited 2020 May 25]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213182s000,213051s001lbl.pdf
   Google Scholar
• Brunton SA, Wysham CH. GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date. Postgrad Med. 2020;132(S2):3–14.
   Google Scholar
• Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381:841–851.
   PubMed Web of Science ®Google Scholar
• Mosenzon O, Blicher TM, Rosenlund S, et al. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019;7:515–527.
   PubMed Web of Science ®Google Scholar
• Aroda VR, Bauer R, Herts CL, et al. Efficacy and safety of oral semaglutide by baseline age in the PIONEER clinical trial program. Diabetes. 2020;69(Suppl 1):932-P.
   Google Scholar
• Bækdal TA, Thomsen M, Kupčová V, et al. Pharmacokinetics, safety, and tolerability of oral semaglutide in subjects with hepatic impairment. J Clin Pharmacol. 2018;58(10):1314–1323.
   PubMed Web of Science ®Google Scholar
• Meier J, Granhall C, Hoevelmann U, et al. Effect of upper gastrointestinal disease on the pharmacokinetics of oral semaglutide in subjects with type 2 diabetes. Diabetes. 2019;68(Suppl 1):1013–P.
   Web of Science ®Google Scholar
• Bain SC, Mosenzon O, Arechavaleta R, et al. Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: rationale, design and patient baseline characteristics for the PIONEER 6 trial. Diabetes Obes Metab. 2019;21(3):499–508.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Appendix 1. Guidance for industry: diabetes mellitus – evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. 2008 [cited 2020 May 25]. Available from: https://www.fda.gov/media/121272/download
   Google Scholar
• Bydureon® (exenatide extended-release) prescribing information [updated Feb 2020; cited 2020 May 25]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022200s030lbl.pdf
   Google Scholar
• Trulicity® (dulaglutide) prescribing information [updated Feb 2020; cited 2020 May 25]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125469s033lbl.pdf
   Google Scholar
• Victoza® (liraglutide) prescribing information [updated June 2019; cited 2020 May 25]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022341s031lbl.pdf
   Google Scholar
• Ozempic® (semaglutide) prescribing information [updated Jan 2020; cited 2020 May 25]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209637s003lbl.pdf
   Google Scholar
• Invokana® (canagliflozin) prescribing information [updated Jan 2020; cited 2020 May 25]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204042s036lbl.pdf
   Google Scholar
• Jardiance® (empagliflozin) prescribing information [updated Jan 2020; cited 2020 May 25]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204042s011lbl.pdf
   Google Scholar
• Tella SH, Rendell MS. DPP-4 inhibitors: focus on safety. Expert Opin Drug Saf. 2015;14(1):127–140.
   PubMed Web of Science ®Google Scholar
• Husain M, Bain SC, Jeppesen OK, et al. Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk. Diabetes Obes Metab. 2020;22:442–451.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A heart disease study of semaglutide in patients with type 2 diabetes (SOUL), identifier NCT03914326 [ cited 2020 May 25]. Available from: https://clinicaltrials.gov/ct2/show/NCT03914326
   Google Scholar
• Aroda VR, Rosenstock J, Terauchi Y, et al. PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care. 2019;42(9):1724–1732.
   PubMed Web of Science ®Google Scholar
• Rodbard HW, Rosenstock J, Canani LH, et al. Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial. Diabetes Care. 2019;42(12):2272–2281.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Allison D, Birkenfeld AL, et al. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial. JAMA. 2019;321(15):1466–1480.
   PubMed Web of Science ®Google Scholar
• Pratley R, Amod A, Hoff ST, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019;394(10192):39–50.
   PubMed Web of Science ®Google Scholar
• Pieber TR, Bode B, Mertens A, et al. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019;7(7):528–539.
   PubMed Web of Science ®Google Scholar
• Zinman B, Aroda VR, Buse JB, et al. Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PIONEER 8 trial. Diabetes Care. 2019;42(12):2262–2271.
   PubMed Web of Science ®Google Scholar
• Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013;36:1384–1395.
   PubMed Web of Science ®Google Scholar
• Bethel MA, Patel RA, Merrill P, et al. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol. 2018;6:105–113.
   PubMed Web of Science ®Google Scholar
• Kristensen SL, Røth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7:776–785.
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhang X, Chai S, et al. Risk of malignant neoplasia with glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes: a meta-analysis. J Diabetes Res. 2019;2019:1534365.
   PubMed Web of Science ®Google Scholar
• Granhall C, Søndergaard FL, Thomsen M, et al. Pharmacokinetics, safety and tolerability of oral semaglutide in subjects with renal impairment. Clin Pharmacokinet. 2018;57:1571–1580.
   PubMed Web of Science ®Google Scholar
• Davies MJ, Bain SC, Atkin SL, et al. Efficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a randomized clinical trial. Diabetes Care. 2016;39:222–230.
   PubMed Web of Science ®Google Scholar
• Lyseng-Williamson KA. Glucagon-like peptide-1 receptor analogues in type 2 diabetes: their use and differential features. Clin Drug Investig. 2019;39:805–819.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Semaglutide effects on heart disease and stroke in patients with overweight or obesity (SELECT), identifier NCT03574597 [ cited 2020 May 25]. Available from: https://clinicaltrials.gov/ct2/show/NCT03574597
   Google Scholar
• ClinicalTrials.gov. A research study to see how semaglutide works compared to placebo in people with type 2 diabetes and chronic kidney disease (FLOW), identifier NCT03819153. [ cited 2020 May 25]. Available from: https://clinicaltrials.gov/ct2/show/NCT03819153
   Google Scholar
• ClinicalTrials.gov. A research study to look at how semaglutide compared to placebo affects diabetic eye disease in people with type 2 diabetes (FOCUS), identifier NCT03811561 [ cited 2020 May 25]. Available from: https://clinicaltrials.gov/ct2/show/NCT03811561
   Google Scholar
• Donsmark M, Borregaard J, Breitschaft A, et al. Evaluation of the effects of water volume with dosing and post-dose fasting period on pharmacokinetics of oral semaglutide. Diabetologia. 2017;60(Suppl 1):S1–S608. Abstract 792.
   PubMedGoogle Scholar
• Maarbjerg SJ, Borregaard J, Breitschaft A, et al. Evaluation of the effect of food on the pharmacokinetics of oral semaglutide. Diabetologia. 2017;60(Suppl 1):S1–S608. Abstract 148.
   PubMedGoogle Scholar
• Brunton SA, Mosenzon O, Wright EE. Integrating oral semaglutide into clinical practice in primary care: for whom, when, and how? Postgrad Med. 2020;132(S2):48–60.
   Google Scholar